B
Basilea Pharmaceutica AG Allschwil
SWB:PK5
Basilea Pharmaceutica AG Allschwil
SWB:PK5
Price:
58
EUR
-0.85%
Market Closed
Market Cap:
€700.1m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
B
|
Basilea Pharmaceutica AG Allschwil
SWB:PK5
|
CH |
|
K
|
Khon Kaen Sugar Industry PCL
SET:KSL
|
TH |
|
Raymond Ltd
NSE:RAYMOND
|
IN |
|
Kallo Inc
OTC:KALO
|
CA |
|
B
|
Banpu PCL
SET:BANPU
|
TH |
|
Energy of Minas Gerais Co
BOVESPA:CMIG4
|
BR |
|
G
|
Go Digit General Insurance Ltd
NSE:GODIGIT
|
IN |
|
G
|
G G Engineering Ltd
BSE:540614
|
IN |
|
Belluna Co Ltd
TSE:9997
|
JP |
|
Hauppauge Digital Inc
OTC:HAUP
|
US |
|
S
|
Shin Shin Natural Gas Co Ltd
TWSE:9918
|
TW |
|
York Water Co
NASDAQ:YORW
|
US |
|
Frontier Services Group Ltd
HKEX:500
|
HK |
|
Dynemic Products Ltd
NSE:DYNPRO
|
IN |
|
Sac's Bar Holdings Inc
TSE:9990
|
JP |
|
CIELO SA Instituicao de Pagamento
F:28MA
|
BR |
Relative Value
The Relative Value of one PK5 stock under the Base Case scenario is hidden EUR. Compared to the current market price of 58 EUR, Basilea Pharmaceutica AG Allschwil is hidden .
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
PK5 Relative Value
HIDDEN
Multiples Across Competitors
PK5 Competitors Multiples
Basilea Pharmaceutica AG Allschwil Competitors
Basilea Pharmaceutica AG Allschwil Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CH |
B
|
Basilea Pharmaceutica AG Allschwil
SWB:PK5
|
712.9m EUR | 2.8 | 16.1 | 10.6 | 11 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
362.5B USD | 5.9 | 86.6 | 14.4 | 20 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187.5B USD | 5.1 | 24.3 | 14.1 | 14.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
170.3B USD | 5.8 | 20 | 12.5 | 15.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
115.3B USD | 9.6 | 29.2 | 21.9 | 22.9 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
77.5B USD | 5.4 | 17.2 | 12.6 | 14.4 | |
| AU |
|
CSL Ltd
ASX:CSL
|
66.8B AUD | 3.1 | 34.3 | 11.3 | 14.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
41.3B USD | 11.1 | 131.9 | 73.8 | 82 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
